title: Analysis of the kinetics of prothrombin activation and evidence that two equilibrating forms of prothrombinase are involved in the process.
abstract: Prothrombinase cleaves prothrombin at Arg(271) and Arg(320) to produce thrombin. The kinetics of cleavage of five recombinant prothrombins were measured: wild-type prothrombin (WT-II), R155A/R284A/R271A prothrombin (rMZ-II), R155A/R284A/R320A prothrombin (rP2-II), S525C prothrombin labeled with fluorescein (WT-II-F*), and R155A/R284A/R271A/S525C prothrombin labeled with fluorescein (rMZ-II-F*). rMZ-II and rP2-II are cleaved only at Arg(320) and Arg(271), respectively, to yield the intermediates meizothrombin and prethrombin-2, respectively. WT-II-F* and rMZ-II-F* were labeled at Cys(525) with fluorescein; cleavage was monitored by enhanced fluorescence. Activation kinetics of WT-II, rMZ-II, and rP2-II indicated that the catalytic efficiency of cleavage at Arg(320) was increased by 30,000-fold by the cofactor factor Va, as was the conversion of prothrombin to thrombin. However, factor Va increased cleavage at Arg(271) only by 34-fold. Although WT-II competitively inhibited cleavage of WT-II-F*, rMZ-II or rP2-II did not inhibit completely even at saturating concentrations. However, rMZ-II and rP2-II together inhibited WT-II-F* cleavage competitively. Both WT-II and rMZ-II competitively inhibited rMZ-II-F* cleavage, whereas rP2-II did not. A model of prothrombin activation that includes two equilibrating forms of prothrombinase, each recognizing one of the cleavage sites, is quantitatively consistent with all of the experimental observations. Therefore, we conclude that the kinetics of prothrombin activation can be described by a "ping-pong"-like mechanism.
authors.affiliation: Department of Biochemistry, Queen's University, Kingston, Ontario K7L 3N6, Canada.
authors.forename: Nicole
authors.initials: N
authors.lastname: Brufatto
authors.forename: Michael E
authors.initials: ME
authors.lastname: Nesheim
mesh_terms: D001120:Arginine / Q000737:chemistry; D001665:Binding Sites; D001667:Binding, Competitive; D004247:DNA / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004591:Electrophoresis, Polyacrylamide Gel; D004792:Enzyme Precursors / Q000737:chemistry; D015943:Factor Va / Q000737:chemistry; D019793:Fluorescein / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008954:Models, Biological; D008962:Models, Theoretical; D016297:Mutagenesis, Site-Directed; D011516:Prothrombin / Q000737:chemistry* / Q000378:metabolism*; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D013917:Thrombin / Q000737:chemistry; D013925:Thromboplastin / Q000378:metabolism*; D013997:Time Factors
chemical_list: D004792:Enzyme Precursors; D011994:Recombinant Proteins; D015943:Factor Va; D011516:Prothrombin; D004247:DNA; D013925:Thromboplastin; D001120:Arginine; D013917:Thrombin; C026812:meizothrombin; D019793:Fluorescein